This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Cell-Wave Study: Combined Extracorporal Shock Wave Therapy and Intracoronary Cell Therapy in Chronic Ischemic Myocardium

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
A. M. Zeiher, Johann Wolfgang Goethe University Hospital
ClinicalTrials.gov Identifier:
NCT00326989
First received: May 16, 2006
Last updated: March 20, 2017
Last verified: March 2017
  Purpose

Extracorporal shock wave therapy is performed prior to cell therapy for induction of therapeutic neovascularization and improvement of homing of bone marrow progenitor cells in patients with chronic ischemic heart disease following anterior myocardial infarction.

Shock waves can induce growth factor expression in the ischemic myocardium and might augment homing of autologous bone marrow mononuclear cells which are injected intracoronary 24 h following shock wave therapy


Condition Intervention Phase
Congestive Heart Failure Procedure: intracoronary stem cell therapy Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Extracorporal Shock Wave Therapy for Induction of Therapeutic Neovascularization and Homing of Bone Marrow Progenitor Cells in Patients With Chronic Ischemic Heart Disease

Resource links provided by NLM:


Further study details as provided by A. M. Zeiher, Johann Wolfgang Goethe University Hospital:

Primary Outcome Measures:
  • Improvement in global ejection fraction on LV angiography [ Time Frame: 4 months ]

Secondary Outcome Measures:
  • Global or regional wall motion at 4 months and 1 year [ Time Frame: 4 months ]
  • NYHA Class [ Time Frame: 4 months ]
  • NT BNP levels [ Time Frame: 4 months ]
  • MACE [ Time Frame: 4 months ]
  • Life quality [ Time Frame: 4 months ]

Enrollment: 103
Study Start Date: May 2006
Study Completion Date: December 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Low-dose shock wave treatment & Placebo Procedure: intracoronary stem cell therapy
extracorporal shock waves prior to intracoronary cell therapy
Active Comparator: low-dose shock-wave treatment & Cell therapy Procedure: intracoronary stem cell therapy
extracorporal shock waves prior to intracoronary cell therapy
Active Comparator: High-dose shock-wave treatment & Placebo Procedure: intracoronary stem cell therapy
extracorporal shock waves prior to intracoronary cell therapy
Active Comparator: High-dose shock-wave treatment & cell therapy Procedure: intracoronary stem cell therapy
extracorporal shock waves prior to intracoronary cell therapy
Active Comparator: Placebo shock-wave treatment & cell therapy Procedure: intracoronary stem cell therapy
extracorporal shock waves prior to intracoronary cell therapy

Detailed Description:
Single center, Phase I-II Study (Safety, Feasibility and Efficacy) Double-blind, randomised trial (Cell therapy), single blind (Shockwave)
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with chronic ischemic heart disease
  • Patients with anterior myocardial infarction > 3months
  • EF < 50% or NYHA II-IV
  • Age 18-80
  • Informed consent

Exclusion Criteria:

  • Ventricular thrombus
  • Infarct < 3 months.
  • Active infection or fever
  • Chronic inflammatory disease (e.g M. Crohn, Rheumatoid Arthritis)
  • HIV Infection oder active Hepatitis
  • Neoplastic disease w/o complete remission within 5 years
  • Stroke < 3months
  • Creatinine > 2 mg/dl
  • Relevant Liver disease (GOT > twice the upper limit).
  • Anemia (Hemoglobin <10 mg/dl)
  • Thrombocytopenia < 100.000/µl
  • Allergies to Aspirin, Clopidogrel, Heparin
  • History of bleeding disorder
  • History of coagulopathy
  • Gastrointestinal Bleeding < 3 months
  • Surgery or Trauma < 2 months
  • Pregnancy
  • Mental Retardation
  • Participation in other clinical study < 1 month
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00326989

Locations
Germany
Div. of Cardiology , University of Frankfurt
Frankfurt, Germany, 60590
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospital
Investigators
Principal Investigator: Andreas M Zeiher, MD Div. of Cardiology, University of Frankfurt, Germany
Study Director: Dirk H Walter, MD Div. of Cardiology, University of Frankfurt
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: A. M. Zeiher, Prof. Dr. Andreas M. Zeiher, Johann Wolfgang Goethe University Hospital
ClinicalTrials.gov Identifier: NCT00326989     History of Changes
Other Study ID Numbers: 2005-005709-50
Cellwave CHF
Study First Received: May 16, 2006
Last Updated: March 20, 2017

Keywords provided by A. M. Zeiher, Johann Wolfgang Goethe University Hospital:
Extracorporal shock wave therapy
Cell therapy

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on August 21, 2017